KPR Mill update

Reasons for buying:

Market Cap: ₹18,405 Cr (Bluechip stock)

Debt to Equity: 0.2

Return on Equity 5Y Avg: 23.14%

EPS - 5Y Growth: 26.92%

Price-earnings to growth (5Y): 0.83

5Y RoE Consistency - Sustained without losing 20% in any year

Buy date: 1-Aug-2022

Qty: 16 Price: ₹588.35 Buy EPS: 26.21

Buy date: 28-Oct-2022

Qty: 18 Price: ₹529 Buy EPS: 26.21

Will continue to add when a stock falls 10% as long as the ratios remain the same. The stock would take a long time to pay, it lost 10% since I bought it in August.

KPR Mill is an apparel manufacturer, securing revenues predominantly from India. It is mainly engaged in the business of manufacturing textiles consisting of yarn, fabrics, readymade garments, and wind power. Its core products are readymade knitted apparel, fabrics, melange, carded, and combed yarn. Its secondary segment includes sugar and others. The company has its production facilities in the state of Tamil Nadu in India.

Muthoot Finance Options update

Date: 30-09-2022

Sold MUTHOOTFIN OCT 800 PE lot 375 at ₹5 for a premium of ₹1875.

The margin required ₹51792.88 it will be a cash-secured put.

Reasons for selling:

The previous close was ₹1033

The strike price is 105 which is 23% lower and there are 27 days for expiry. Sold because the strike price is 23% below market price and even if it gets allocated I will try to do a wheel strategy.

Max loss is ₹3,00,000 if the company goes bankrupt.

Date: 27-10-2022

The option expired worthless, the price closed at ₹1041 and went as low as ₹1007.45 in between and made ₹1875. Was looking for a similar deal this month but could find any have to check the options chart.

Tech Mahindra Options update

Date: 30-09-2022

Sold TECHM OCT 800 PE at ₹2.35 for a premium of ₹1410.

Margin required ₹57,770.39.

Reasons for selling:

The previous close was ₹1,007

The strike price is ₹800 which is 20% lower and there are 27 days for expiry. Last time I made a profit of 100% in this stock, and even if it gets allocated I will try to do a wheel strategy.

Max loss is ₹4,80,000 if the company goes bankrupt.

Date: 27-10-2022

The option expired worthless, the price closed at ₹1075 and went as low as ₹984 in between and made ₹1410. Was looking for a similar deal this month but could find any have to check the options chart.

Jubilant Pharmova update

Reasons for buying:

Buy PE was reasonable at 10.64 and below 10 years PE median of 14.83.

Earnings have increased 6 times since 2013.

Return on equity is ok at 16.16%.

The market cap of the company is ₹10,006.84cr.

The debt of the company is ₹2,583.97cr with ₹671.32cr in cash. The debt is higher than my other investments but I think it's cheap, have to wait and see if I can make money on it.

Buy date: 28-Sep-2021

Qty: 16 Buy Price: ₹607 Buy EPS: ₹57.03 Buy PE: 10.64

Sell date: 27-Oct-2022

Qty:16 Price: ₹349.65 EPS: ₹10.24 PE: 34.14

The price of the stock is up about 3.19% from my buy price.

I have sold it at a loss of -₹4,037.6 after holding it for 394 days, I should not have bought it in the first place since it did not satisfy any of my rules. The earnings have dropped 82% from ₹57.03 to ₹10.24 and it is good that I have not added to stock when EPS dropped.

It is an integrated global pharmaceutical company with three business segments: Pharmaceuticals, Contract Research & Development services, and proprietary novel drugs.

Quick Heal Technologies

Buy Date: 17-Dec-2021

Qty: 43 Price: ₹227.8 EPS: ₹14.69 PE:15.5

I will not add to this stock even when the price drops.

I have purchased this stock since it has zero debt and cash of around ₹332cr after the buyback.

Buyback Date: 25-Oct-2022 Holding days: 312

Qty:12 Price: ₹300 EPS: ₹11.12 PE: 26.97

Quick Heal Technologies is an India-based IT security solutions company. It is engaged in offering software security products and solutions. The company serves clients in various industries including manufacturing. BFSI, healthcare, hospitality, educational institutions, government organizations, emerging e-commerce, and the service sector. The group reports the operating segments based on the target customer groups to bring Retail; Enterprise and Government; and Mobile. It has a business presence in India and foreign countries, of which maximum revenue is derived within India. Its product range consists of Quick Heal Total Security, Quick Heal AntiVirus Pro, Quick Heal Total Security for Mac, Quick Heal PCTuner 3.0, and Guardian NetSecure.

Cyient update

Ex-Dividend date 25-10-2022 ₹10 per share. Received ₹130 the cost basis is ₹9630.4.

I just wanted to try dividend investing, will check yearly to see how it performed.

Buy Date: 17-Oct-202296

Qty: 13 Price: ₹750.8 EPS: ₹43.83 Amount: ₹9760.4

Dividend Evaluation Checklist:
3.19	Dividend Yield: Ideally Between 3.5% and 6.5%
The dividend growth is not consistent year on year	Number of Consecutive Years of Dividend Growth: Ideally At Least 10
41.17%	Average Annual Dividend Growth: Ideally between 5% and 10%
12.62%	Average Annual Earnings Growth: Ideally in line with or above dividend growth rates.
54.78	Dividend Payout Ratio: Ideally less than 75%, except for REITs and MLPs
0.52	Debt to Equity Ratio: Ideally 1:1 or less
11.52	Net Margins: Ideally at least 5%
16.29	Return on Equity: Ideally at least 10%
949	Fair Value Estimate: Ideally trading below Morningstar’s Fair Value Estimate
750.8	Current Price

I will continue to invest only when EPS increases and the price falls.

I am going to sell it at Morningstar's Fair Value.

Cyient provides a variety of information technology, IT, and engineering services. The firm organizes itself into two segments based on customer type and reported as either service or design-led manufacturing revenue. Services are by far the largest activity. The industries served are aerospace and defense, communications, energy and utilities, transportation, medical and healthcare, semiconductor, and portfolio which focuses on the development and implementation of new technologies in all sectors. The majority of the company's revenue comes from America.

EDELWEISS FINANCIAL SERVICES LIMITED NCD

I have subscribed for EDELWEISS FINANCIAL SERVICES LIMITED NCD 89EFSL25 tenure 3 years series III 8.9% yield monthly payment via goldenpi.

Axis Midcap fund

I have started investing in the Axis Midcap fund because it appeared in the Mint 20 mutual fund schemes to invest in. I started with ₹500 and probably will continue with SIP.

Granules India update

PE was reasonable.

Buy PE of 19.64 is above 10 years PE median of 15.07.

Earnings have been increasing since 2012.

Return on equity is good at 27%.

Debt is 892.10cr and ₹393.80cr cash.

The market cap of the company is ₹7,831.48cr.

Buy date: 21-Dec-2020

Qty: 29   Buy Price: ₹342.3    Buy EPS: 17.42    Buy PE: 19.64

The stock has fallen 10% but the earnings improved so I have added 32 shares.

Buy date: 18-Mar-2021

Qty: 32   Buy Price: ₹307.75    Buy EPS: 20.53    Buy PE: 15.85

Q4 results were released on May 11th and the current EPS is 22.18 which increased by 27.32% and 8.04% from my buy EPS.

The price of the stock is down about -2.4% from my average buy price.

Buy date: 12-May-2022

Qty: 41   Buy Price: ₹239    Buy EPS:₹17.15    Buy PE: 13.93

Buyback: 17-Oct-2022

Qty: 29    Sold Price: ₹400    Sold EPS:₹16.89    Sold PE: 23.68

Granules India is an India-based pharmaceutical company. The company manufactures active pharmaceutical ingredients, pharmaceutical formulation intermediates, and finished dosages. Its business is organized into three areas; the Core business which comprises core molecules such as Paracetamol, Ibuprofen, Metformin, Guaifenesin, and Methocarbamol; the emerging business focuses on manufacturing APIs and the US Generics. Its primary geographic markets are North America, Latin America, Europe, India, and the Rest of the World.

Disclaimer: The video is for educational purposes and for my friends and family. I am not a financial advisor and do not consider it as buy or sell. Taking advice from a random guy on the internet is harmful to your portfolio. I do not do a deep analysis of stocks I buy them just as a hobby.

Sandur Manganese and Iron Ores added

Reasons for buying:

Buy PE was reasonable at 3.38 and below 10 years PE median of 11.94.

Earnings have increased since 2016.

Return on equity is at 75%.

The market cap of the company is ₹1,892cr.

The debt of the company is ₹308cr with ₹1114cr in cash.

Buy date: 22-Feb-2022

Qty: 9 Buy Price: ₹920.02 Buy EPS: 189.03 Buy PE: 4.86

Buy date: 11-Oct-2021

Qty: 12 Buy Price: ₹828 Buy EPS: 208.67 Buy PE: 3.96

Buy date: 14-Oct-2022

Qty: 14 Buy Price: ₹705.9 Buy EPS: 208.67 Buy PE: 3.38

I will stop buying when EPS drops to 46 or when R1 is not satisfied.

Sandur Manganese and Iron Ores is a mining company. It is engaged in the mining of manganese and iron ore. The company is also engaged in the manufacture of ferroalloys. Its operating segment includes Mining and Ferroalloys and Coke and energy. The company generates maximum revenue from the Coke and Energy segment. Geographically, it derives all of its revenue from India.

IG Petrochemicals added

Reasons for buying:

Buy PE was reasonable at 11.84 and above 10 years PE median of 10.54.

Earnings have increased 14 times since 2012 although not consistently.

Return on equity is ok at 25.86%.

The market cap of the company is ₹2,846.21cr.

The debt of the company is ₹163.91cr with ₹83.55cr in cash.

Buy date: 11-Oct-2021

Qty: 10 Buy Price: ₹913 Buy EPS: 77.08 Buy PE: 11.84

The price of the stock is down about -23.11% from my buy price. I will stop buying when EPS drops to 45.65.

Buy date: 20-Oct-2021

Qty: 12 Buy Price: ₹821.00 Buy EPS: 77.08 Buy PE: 10.65

The earnings have increased by 17.64%.

Buy date: 17-Nov-2021

Qty: 13 Buy Price: ₹722.00 Buy EPS: 90.68 Buy PE: 7.96

Buy date: 25-Jan-2022

Qty: 15 Buy Price: ₹639.00 Buy EPS: 90.68 Buy PE: 7.047

Buy date: 12-Oct-2022

Qty: 18 Buy Price: ₹547 Buy EPS: 95.47 Buy PE: 5.72

I will sell when EPS falls below 45.65 or R1 is not satisfied.

IG Petrochemicals Ltd is engaged in the manufacture and sale of organic chemicals. It produces Phthalic Anhydride, Maleic Anhydride, and Benzoic Acid. The Phthalic Anhydride is used for the manufacture of polyvinyl chloride products for the manufacturing of a range of consumer care, personal care, and home care products like shoes, pipes and hoses, boxes, containers, packaging films, medical and surgical equipment, and others. In addition, it is also used as the thermostat for the manufacture of fiberglass-reinforced plastics for the automobile, construction, marine, and transportation industries. Geographically, the firm has a presence in both the Indian and international markets of which the Indian region accounts for the majority of revenue.

Gujarat State Fertilizers & Chemicals

This is part of book value investing

PB<.5

Book value growth 10Y and 5Y more than 10%.

Book Value: 295

Buy date: 10-Oct-2022

Qty: 76 Price: ₹130.85 EPS: ₹27.81 PB: 0.44

I will sell at book value and plan to update the GTT order in Zerodha every week by checking Tradeview. If the book value decreases I will lose money otherwise hoping the company can increase book value and sell it at book value a few years from now. Usually, book value investing takes at least 5 years and in some cases can hit PB =1 once in 10 years.

Book value investing

I am planning to invest based on the book value of stocks. The criteria are to invest in stocks where the book value has increased by at least 10% in 1, 5, and 10 years. Low debt and profitable companies with P/B less than .5.

Dividend Investing Strategy Guide

 Dividend Evaluation Checklist:

• Dividend Yield: Ideally Between 3.5% and 6.5%
• Number of Consecutive Years of Dividend Growth: Ideally At Least 10
• Average Annual Dividend Growth: Ideally between 5% and 10%
• Average Annual Earnings Growth: Ideally in line with or above dividend growth rates.
• Dividend Payout Ratio: Ideally less than 75%, except for REITs and MLPs
• Debt to Equity Ratio: Ideally 1:1 or less
• Net Margins: Ideally at least 5%
• Return on Equity: Ideally at least 10%
• Fair Value Estimate: Ideally trading below Morningstar’s Fair Value Estimate

https://www.marketbeat.com/dividends/dividend-investing-guide/#A-Warning-About-Using-Dividend-Lists

Some sites to get dividend ideas

S&P BSE Dividend Stability Index

NIFTY Dividend Opportunities 50 Index

MSCI India High Dividend Yield Index

Morningstar India Dividend Yield Focus

https://economictimes.indiatimes.com/markets/stocks/news/20-dividend-aristocrats-that-make-nifty50s-20-year-return-look-pale/articleshow/86058745.cms

https://www.valueresearchonline.com/stories/51505/playing-the-dividend-game/

Kopran added

Reasons for buying:

Buy PE was reasonable at 19.43 and above 10 years PE median of 11.22.

The 5-year earnings average is 25.2% and earnings are lackluster.

Return on equity is good at 28.34% but the 5-year average is 17.67%.

The market cap of the company is ₹1,285.05 Cr.

The debt of the company is ₹66.30 Cr with ₹7.98 Cr in cash.

Buy date: 28-Apr-2022

Qty: 38 Buy Price: ₹263 Buy EPS: 13.53 Buy PE: 19.43

***

Buy date: 12-May-2022

Qty: 42 Buy Price: ₹229.85 Buy EPS: 13.54 Buy PE: 16.98

***

Buy date: 06-July-2022

Qty: 50 Buy Price: ₹196.7 Buy EPS: 14.24 Buy PE: 13.81

***

Buy date: 16-Aug-2022

Qty: 54 Buy Price: ₹184 Buy EPS: 13.86 Buy PE: 13.27

***

Buy date: 03-Oct-2022

Qty: 63 Buy Price: ₹157 Buy EPS: 13.86 Buy PE: 11.32

I will stop buying when EPS drops to 13.15 since I have purchased at 20 PE.

Kopran Ltd. is a holding company, which engages in the manufacturing of pharmaceuticals and related products. It operates through the following business units: Formulations, and Active Pharmaceutical Ingredients. The firm's products include Amyn, Lokit, and Ciproquin. The company was founded on April 26, 1958, and is headquartered in Mumbai, India.